Hepatotoxicity papaverine

Papaverine is not FDA approved for erectile dysfunction. Intracavernosal papaverine alone is not commonly used for management of erectile dysfunction because large doses are required, and these produce dose-related adverse effects priapism, corporal fibrosis, hypotension, and hepatotoxicity. Papaverine is more often administered in lower doses combined with phentolamine and/or alprostadil. A variety of formulae have been used, but no one mixture has been proven better than other mixtures (see Table 81-6). Combination formulations are considered to be safer and associated with the potential for fewer serious adverse effects than high doses of any one of these agents. ... 

Brown SL, Haas CA, Koehler M, et al. Hepatotoxicity related to intracavernous pharmacotherapy with papaverine. Urology 1998 52 844-847. 

Kiaer, H. W., Olsen, S. and Ronnov-Jessen, V. (1974) Hepatotoxicity of papaverine - histologic lesions. Arch. Pathol., 98, 292. 

---

See also in sourсe #XX -- [ ]

---